Loading...
Glimepride 1mg + Metformin 500mg (Sr) + Pioglitazone 15 mg
A triple-action oral antidiabetic formulation developed for comprehensive management of type 2 diabetes mellitus. STELTOG-GP1 combines glimepiride, sustained-release metformin, and pioglitazone to improve insulin secretion, reduce hepatic glucose production, and enhance peripheral insulin sensitivit.
A triple-action oral antidiabetic formulation developed for comprehensive management of type 2 diabetes mellitus. STELTOG-GP1 combines glimepiride, sustained-release metformin, and pioglitazone to improve insulin secretion, reduce hepatic glucose production, and enhance peripheral insulin sensitivity for effective long-term glycemic control.
Contains Glimepiride (a sulfonylurea), Metformin SR (a biguanide), and Pioglitazone (a thiazolidinedione), offering a multi-pathway approach to regulate blood glucose levels in patients with type 2 diabetes.
Glimepiride stimulates pancreatic β-cells to release insulin, helping reduce elevated blood glucose levels, especially after meals.
Metformin decreases glucose production in the liver and improves peripheral glucose uptake, contributing to better insulin sensitivity and reduced insulin resistan...
Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.
